GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for controlling common lymphoma
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, lenalidomide, and rituximab) in 60 people with untreated stage III-IV follicular lymphoma. The goal is to see how well these drugs work together to shrink or control the cancer. Participants must have a specific type o…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 07:35 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togethe…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 17, 2026 07:34 UTC
-
New hope for hard-to-treat lymphoma patients as drug combos tested
Disease control OngoingThis study is for people with a slow-growing type of blood cancer called follicular lymphoma that has come back or is not responding to treatment. It compares the drug obinutuzumab alone versus obinutuzumab combined with other drugs (umbralisib, lenalidomide, or chemotherapy) to …
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug cocktail shows promise for lymphoma patients
Disease control OngoingThis study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in 40 people with untreated stage II-IV follicular lymphoma. The goal is to see if the combination works better than each drug alone at shrinking tumors. Participants receive all three drugs a…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug duo shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests whether combining two drugs—obinutuzumab and ibrutinib—can shrink or eliminate slow-growing non-Hodgkin's lymphoma in people who haven't been treated before. About 30 adults with various stages of the disease will receive the drugs as their first therapy. The goa…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo therapy aims to boost CAR T-Cell power against lymphoma
Disease control OngoingThis early-phase study tests whether adding the drug acalabrutinib to CAR T-cell therapy (axicabtagene ciloleucel) is safe and works better for people with certain B-cell lymphomas. About 23 adults whose cancer has not responded to prior treatments will receive the combination. T…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for Tough-to-Treat lymphoma: targeted drug shows promise
Disease control OngoingThis study tests a drug called ibrutinib in 41 adults with follicular lymphoma that has come back or no longer responds to standard treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shr…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC